Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates

Objective:the objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment.study design:retrospective study of neonates with thrombosis treated between january 2008 and december 2014.result:nineteen premature and 21 term neonates were treated with whole milligram doses of enoxaparin. the mean starting and therapeutic enoxaparin doses were 1.72±0.17 and 1.86±0.17 mg kg−1, respectively. twenty-five (64%) reached therapeutic antifactor xa (anti-xa) levels with the starting dose, whereas 14 (36%) required dose adjustments. one neonate reached a supratherapeutic anti-xa level (>1.0 iu ml−1) in the loading phase. no bleeding episodes occurred. the mean treatment duration was 12 weeks. among 34 (85%) evaluable patients, 23 (68%) had a complete response, 9 (26%) partial and 2 (6%) had a stable thrombotic state.conclusion:whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates.